{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T10:49:32Z","timestamp":1792838972938,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,12]],"date-time":"2021-01-12T00:00:00Z","timestamp":1610409600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,1,12]],"date-time":"2021-01-12T00:00:00Z","timestamp":1610409600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003921","name":"Department of Health, Australian Government","doi-asserted-by":"publisher","award":["MRFF APP1152418"],"award-info":[{"award-number":["MRFF APP1152418"]}],"id":[{"id":"10.13039\/501100003921","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pregnancy Childbirth"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Severe early onset (less than 34\u2009weeks gestation) intrahepatic cholestasis of pregnancy (ICP) affects 0.1% of pregnant women in Australia and is associated with a 3-fold increased risk of stillbirth, fetal hypoxia and compromise, spontaneous preterm birth, as well as increased frequencies of pre-eclampsia and gestational diabetes. ICP is often familial and overlaps with other cholestatic disorders.<\/jats:p>\n                <jats:p>Treatment options for ICP are not well established, although there are limited data to support the use of ursodeoxycholic acid (UDCA) to relieve pruritus, the main symptom. Rifampicin, a widely used antibiotic including in pregnant women, is effective in reducing pruritus in non-pregnancy cholestasis and has been used as a supplement to UDCA in severe ICP. Many women with ICP are electively delivered preterm, although there are no randomised data to support this approach.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We have initiated an international multicentre randomised clinical trial to compare the clinical efficacy of rifampicin tablets (300\u2009mg bd) with that of UDCA tablets (up to 2000\u2009mg daily) in reducing pruritus in women with ICP, using visual pruritus scores as a measuring tool.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>Our study will be the first to examine the outcomes of treatment specifically in the severe early onset form of ICP, comparing \u201cstandard\u201d UDCA therapy with rifampicin, and so be able to provide for the first-time high-quality evidence for use of rifampicin in severe ICP. It will also allow an assessment of feasibility of a future trial to test whether elective early delivery in severe ICP is beneficial.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial identifiers<\/jats:title>\n                <jats:p>Australian New Zealand Clinical Trials Registration Number (ANZCTR): <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?id=374510\">12618000332224p<\/jats:ext-link> (29\/08\/2018). <\/jats:p>\n                <jats:p>HREC No: HREC\/18\/WCHN\/36.<\/jats:p>\n                <jats:p>EudraCT number: 2018\u2013004011-44.<\/jats:p>\n                <jats:p>IRAS: 272398.<\/jats:p>\n                <jats:p>NHMRC registration: APP1152418 and APP117853.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12884-020-03481-y","type":"journal-article","created":{"date-parts":[[2021,1,12]],"date-time":"2021-01-12T20:47:24Z","timestamp":1610484444000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["A multi-centre, open label, randomised, parallel-group, superiority Trial to compare the efficacy of URsodeoxycholic acid with RIFampicin in the management of women with severe early onset Intrahepatic Cholestasis of pregnancy: the TURRIFIC randomised trial"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5355-2955","authenticated-orcid":false,"given":"William M.","family":"Hague","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonie","family":"Callaway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Chambers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Chappell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzette","family":"Coat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiska","family":"de Haan-Jebbink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marloes","family":"Dekker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Dixon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jodie","family":"Dodd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Fuller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanne","family":"Gordijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorothy","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oskari","family":"Heikinheimo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemarie","family":"Hennessy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Risto","family":"Kaaja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teck Yee","family":"Khong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Lampio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennie","family":"Louise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Makris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corey","family":"Markus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanns-Ulrich","family":"Marschall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippa","family":"Middleton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben W.","family":"Mol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Newnham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Ovadia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Peek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Shand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Stark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jim","family":"Thornton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"Timonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Warrilow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Williamson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,12]]},"reference":[{"key":"3481_CR1","doi-asserted-by":"crossref","unstructured":"Marathe JA, Lim WH, Metz MP, Scheil W, Dekker GA, Hague WM. A retrospective cohort review of intrahepatic cholestasis of pregnancy in a South Australian population. Eur J Obstet Gynecol Reprod Biol. 2017;218:33\u20138.","DOI":"10.1016\/j.ejogrb.2017.09.012"},{"issue":"3","key":"3481_CR2","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.clindermatol.2016.02.004","volume":"34","author":"C Ovadia","year":"2016","unstructured":"Ovadia C, Williamson C. Intrahepatic cholestasis of pregnancy: recent advances. Clin Dermatol. 2016;34(3):327\u201334.","journal-title":"Clin Dermatol"},{"issue":"6014","key":"3481_CR3","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1136\/bmj.1.6014.870","volume":"1","author":"R Reid","year":"1976","unstructured":"Reid R, Ivey KJ, Rencoret RH, Storey B. Fetal complications of obstetric cholestasis. BMJ. 1976;1(6014):870\u20132.","journal-title":"BMJ"},{"issue":"5","key":"3481_CR4","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1097\/AOG.0000000000001693","volume":"128","author":"R Furrer","year":"2016","unstructured":"Furrer R, Winter K, Schaffer L, Zimmermann R, Burkhardt T, Haslinger C. Postpartum blood loss in women treated for intrahepatic cholestasis of pregnancy. Obstet Gynecol. 2016;128(5):1048\u201352.","journal-title":"Obstet Gynecol"},{"issue":"4","key":"3481_CR5","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1002\/hep.21111","volume":"43","author":"A Ropponen","year":"2006","unstructured":"Ropponen A, Sund R, Riikonen S, Ylikorkala O, Aittomaki K. Intrahepatic cholestasis of pregnancy as an indicator of liver and biliary diseases: a population-based study. Hepatology. 2006;43(4):723\u20138.","journal-title":"Hepatology"},{"issue":"4","key":"3481_CR6","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1002\/hep.26444","volume":"58","author":"HU Marschall","year":"2013","unstructured":"Marschall HU, Wikstrom Shemer E, Ludvigsson JF, Stephansson O. Intrahepatic cholestasis of pregnancy and associated hepatobiliary disease: a population-based cohort study. Hepatology. 2013;58(4):1385\u201391.","journal-title":"Hepatology"},{"issue":"7","key":"3481_CR7","doi-asserted-by":"publisher","first-page":"3172","DOI":"10.1172\/JCI68927","volume":"123","author":"G Papacleovoulou","year":"2013","unstructured":"Papacleovoulou G, Abu-Hayyeh S, Nikolopoulou E, Briz O, Owen BM, Nikolova V, Ovadia C, Huang X, Vaarasmaki M, Baumann M, et al. Maternal cholestasis during pregnancy programs metabolic disease in offspring. J Clin Invest. 2013;123(7):3172\u201381.","journal-title":"J Clin Invest"},{"issue":"10174","key":"3481_CR8","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/S0140-6736(18)31877-4","volume":"393","author":"C Ovadia","year":"2019","unstructured":"Ovadia C, Seed PT, Sklavounos A, Geenes V, Di Illio C, Chambers J, Kohari K, Bacq Y, Bozkurt N, Brun-Furrer R, et al. Association of adverse perinatal outcomes of intrahepatic cholestasis of pregnancy with biochemical markers: results of aggregate and individual patient data meta-analyses. Lancet. 2019;393(10174):899\u2013909.","journal-title":"Lancet"},{"issue":"2","key":"3481_CR9","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1002\/hep.20336","volume":"40","author":"A Glantz","year":"2004","unstructured":"Glantz A, Marschall HU, Mattsson LA. Intrahepatic cholestasis of pregnancy: relationships between bile acid levels and fetal complication rates. Hepatology. 2004;40(2):467\u201374.","journal-title":"Hepatology"},{"issue":"2","key":"3481_CR10","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1002\/hep.26055","volume":"57","author":"S Abu-Hayyeh","year":"2013","unstructured":"Abu-Hayyeh S, Papacleovoulou G, Lovgren-Sandblom A, Tahir M, Oduwole O, Jamaludin NA, Ravat S, Nikolova V, Chambers J, Selden C, et al. Intrahepatic cholestasis of pregnancy levels of sulfated progesterone metabolites inhibit farnesoid X receptor resulting in a cholestatic phenotype. Hepatology. 2013;57(2):716\u201326.","journal-title":"Hepatology"},{"issue":"1","key":"3481_CR11","doi-asserted-by":"publisher","first-page":"11823","DOI":"10.1038\/s41598-017-11626-x","volume":"7","author":"PH Dixon","year":"2017","unstructured":"Dixon PH, Sambrotta M, Chambers J, Taylor-Harris P, Syngelaki A, Nicolaides K, Knisely AS, Thompson RJ, Williamson C. An expanded role for heterozygous mutations of ABCB4, ABCB11, ATP8B1, ABCC2 and TJP2 in intrahepatic cholestasis of pregnancy. Sci Rep. 2017;7(1):11823.","journal-title":"Sci Rep"},{"issue":"6","key":"3481_CR12","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1002\/hep.27171","volume":"60","author":"X Song","year":"2014","unstructured":"Song X, Vasilenko A, Chen Y, Valanejad L, Verma R, Yan B, Deng R. Transcriptional dynamics of bile salt export pump during pregnancy: mechanisms and implications in intrahepatic cholestasis of pregnancy. Hepatology. 2014;60(6):1993\u20132007.","journal-title":"Hepatology"},{"issue":"51","key":"3481_CR13","doi-asserted-by":"publisher","first-page":"51085","DOI":"10.1074\/jbc.M308321200","volume":"278","author":"L Huang","year":"2003","unstructured":"Huang L, Zhao A, Lew JL, Zhang T, Hrywna Y, Thompson JR, de Pedro N, Royo I, Blevins RA, Pelaez F, et al. Farnesoid X receptor activates transcription of the phospholipid pump MDR3. J Biol Chem. 2003;278(51):51085\u201390.","journal-title":"J Biol Chem"},{"issue":"10201","key":"3481_CR14","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/S0140-6736(19)31270-X","volume":"394","author":"LC Chappell","year":"2019","unstructured":"Chappell LC, Bell JL, Smith A, Linsell L, Juszczak E, Dixon PH, Chambers J, Hunter R, Dorling J, Williamson C, et al. Ursodeoxycholic acid versus placebo in women with intrahepatic cholestasis of pregnancy (PITCHES): a randomised controlled trial. Lancet. 2019;394(10201):849\u201360.","journal-title":"Lancet"},{"key":"3481_CR15","doi-asserted-by":"crossref","unstructured":"Walker KF, Chappell LC, Hague WM, Middleton P, Thornton JG. Pharmacological interventions for treating intrahepatic cholestasis of pregnancy. Cochrane Database Syst Rev. 2020;2020(7).","DOI":"10.1002\/14651858.CD000493.pub3"},{"issue":"5","key":"3481_CR16","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/S0168-8278(98)80234-1","volume":"28","author":"MA Serrano","year":"1998","unstructured":"Serrano MA, Brites D, Larena MG, Monte MJ, Bravo MP, Oliveira N, Marin JJ. Beneficial effect of ursodeoxycholic acid on alterations induced by cholestasis of pregnancy in bile acid transport across the human placenta. J Hepatol. 1998;28(5):829\u201339.","journal-title":"J Hepatol"},{"issue":"5","key":"3481_CR17","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1046\/j.1471-0528.2003.02273.x","volume":"110","author":"J Gorelik","year":"2003","unstructured":"Gorelik J, Shevchuk AI, Diakonov I, de Swiet M, Lab M, Korchev Y, Williamson C. Dexamethasone and ursodeoxycholic acid protect against the arrhythmogenic effect of taurocholate in an in vitro study of rat cardiomyocytes. BJOG. 2003;110(5):467\u201374.","journal-title":"BJOG"},{"key":"3481_CR18","first-page":"CD000493","volume":"6","author":"V Gurung","year":"2013","unstructured":"Gurung V, Middleton P, Milan SJ, Hague W, Thornton JG. Interventions for treating cholestasis in pregnancy. Cochrane Database Syst Rev. 2013;6:CD000493.","journal-title":"Cochrane Database Syst Rev"},{"key":"3481_CR19","doi-asserted-by":"publisher","first-page":"379271","DOI":"10.1155\/2012\/379271","volume":"2012","author":"OM Loto","year":"2012","unstructured":"Loto OM, Awowole I. Tuberculosis in pregnancy: a review. J Pregnancy. 2012;2012:379271.","journal-title":"J Pregnancy"},{"key":"3481_CR20","volume-title":"Tuberculosis and pregnant women: information for clinicians","author":"PH England","year":"2013","unstructured":"England PH. Tuberculosis and pregnant women: information for clinicians. London: Edited by England PH; 2013."},{"issue":"1","key":"3481_CR21","first-page":"75","volume":"82","author":"C De Vloo","year":"2019","unstructured":"De Vloo C, Nevens F. Cholestatic pruritus : an update. Acta Gastroenterol Belg. 2019;82(1):75\u201382.","journal-title":"Acta Gastroenterol Belg"},{"key":"3481_CR22","first-page":"CD008320","volume":"11","author":"W Siemens","year":"2016","unstructured":"Siemens W, Xander C, Meerpohl JJ, Buroh S, Antes G, Schwarzer G, Becker G. Pharmacological interventions for pruritus in adult palliative care patients. Cochrane Database Syst Rev. 2016;11:CD008320.","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"3481_CR23","first-page":"87","volume":"29","author":"E Eggermont","year":"1976","unstructured":"Eggermont E, Logghe N, Van De Casseye W, Casteels-Van Daele M, Jaeken J, Cosemans J, Verstraete M, Renaer M. Haemorrhagic disease of the newborn in the offspring of rifampicin and isoniazid treated mothers. Acta Paediatr Belg. 1976;29(2):87\u201390.","journal-title":"Acta Paediatr Belg"},{"key":"3481_CR24","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.ejogrb.2015.03.020","volume":"189","author":"V Geenes","year":"2015","unstructured":"Geenes V, Chambers J, Khurana R, Shemer EW, Sia W, Mandair D, Elias E, Marschall HU, Hague W, Williamson C. Rifampicin in the treatment of severe intrahepatic cholestasis of pregnancy. Eur J Obstet Gynecol Reprod Biol. 2015;189:59\u201363.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"2","key":"3481_CR25","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.jhep.2009.11.012","volume":"52","author":"JM Stapelbroek","year":"2010","unstructured":"Stapelbroek JM, van Erpecum KJ, Klomp LW, Houwen RH. Liver disease associated with canalicular transport defects: current and future therapies. J Hepatol. 2010;52(2):258\u201371.","journal-title":"J Hepatol"},{"issue":"1","key":"3481_CR26","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.dld.2016.10.006","volume":"49","author":"Y Bacq","year":"2017","unstructured":"Bacq Y, le Besco M, Lecuyer AI, Gendrot C, Potin J, Andres CR, Aubourg A. Ursodeoxycholic acid therapy in intrahepatic cholestasis of pregnancy: results in real-world conditions and factors predictive of response to treatment. Digest Liver Dis. 2017;49(1):63\u20139.","journal-title":"Digest Liver Dis"},{"key":"3481_CR27","doi-asserted-by":"publisher","first-page":"e3799","DOI":"10.1136\/bmj.e3799","volume":"344","author":"LC Chappell","year":"2012","unstructured":"Chappell LC, Gurung V, Seed PT, Chambers J, Williamson C, Thornton JG, Consortium PS. Ursodeoxycholic acid versus placebo, and early term delivery versus expectant management, in women with intrahepatic cholestasis of pregnancy: semifactorial randomised clinical trial. BMJ. 2012;344:e3799.","journal-title":"BMJ"},{"issue":"5","key":"3481_CR28","doi-asserted-by":"publisher","first-page":"667 e661","DOI":"10.1016\/j.ajog.2015.02.012","volume":"212","author":"A Puljic","year":"2015","unstructured":"Puljic A, Kim E, Page J, Esakoff T, Shaffer B, LaCoursiere DY, Caughey AB. The risk of infant and fetal death by each additional week of expectant management in intrahepatic cholestasis of pregnancy by gestational age. Am J Obstet Gynecol. 2015;212(5):667 e661\u20135.","journal-title":"Am J Obstet Gynecol"},{"key":"3481_CR29","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/2046-4053-3-23","volume":"3","author":"W Ganzevoort","year":"2014","unstructured":"Ganzevoort W, Alfirevic Z, von Dadelszen P, Kenny L, Papageorghiou A, van Wassenaer-Leemhuis A, Gluud C, Mol BW, Baker PN. STRIDER: sildenafil therapy in dismal prognosis early-onset intrauterine growth restriction--a protocol for a systematic review with individual participant data and aggregate data meta-analysis and trial sequential analysis. Syst Rev. 2014;3:23.","journal-title":"Syst Rev"},{"key":"3481_CR30","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.preghy.2018.05.004","volume":"13","author":"MA Brown","year":"2018","unstructured":"Brown MA, Magee LA, Kenny LC, Karumanchi SA, McCarthy FP, Saito S, Hall DR, Warren CE, Adoyi G, Ishaku S. The hypertensive disorders of pregnancy: ISSHP classification, diagnosis & management recommendations for international practice. Pregnancy Hypertens. 2018;13:291\u2013310.","journal-title":"Pregnancy Hypertens"},{"issue":"3","key":"3481_CR31","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.diabres.2013.10.012","volume":"103","author":"WHO","year":"2014","unstructured":"WHO. Diagnostic criteria and classification of hyperglycaemia first detected in pregnancy: a World Health Organization Guideline. Diabetes Res Clin Pract. 2014;103(3):341\u201363.","journal-title":"Diabetes Res Clin Pract"},{"issue":"10","key":"3481_CR32","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1586\/17474124.2015.1083857","volume":"9","author":"HU Marschall","year":"2015","unstructured":"Marschall HU. Management of intrahepatic cholestasis of pregnancy. Expert Rev Gastroenterol Hepatol. 2015;9(10):1273\u20139.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"1","key":"3481_CR33","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/j.1365-3016.2010.01166.x","volume":"25","author":"J Gardosi","year":"2011","unstructured":"Gardosi J, Figueras F, Clausson B, Francis A. The customised growth potential: an international research tool to study the epidemiology of fetal growth. Paediatr Perinat Epidemiol. 2011;25(1):2\u201310.","journal-title":"Paediatr Perinat Epidemiol"},{"issue":"7","key":"3481_CR34","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1093\/aje\/kwh090","volume":"159","author":"G Zou","year":"2004","unstructured":"Zou G. A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol. 2004;159(7):702\u20136.","journal-title":"Am J Epidemiol"}],"container-title":["BMC Pregnancy and Childbirth"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12884-020-03481-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12884-020-03481-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12884-020-03481-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,12]],"date-time":"2021-01-12T20:58:50Z","timestamp":1610485130000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpregnancychildbirth.biomedcentral.com\/articles\/10.1186\/s12884-020-03481-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,12]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["3481"],"URL":"https:\/\/doi.org\/10.1186\/s12884-020-03481-y","relation":{},"ISSN":["1471-2393"],"issn-type":[{"value":"1471-2393","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,12]]},"assertion":[{"value":"27 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Primary ethical approval for the Protocol and the Patient information and consent form has been provided by the Women\u2019s and Children\u2019s Hospital Network Human Research Ethics Committee: reference HREC\/18\/WCHN\/36. Written informed consent will be obtained from each participant prior to her undertaking any study procedures.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JC, PD, H-UM, CO and CW consult for Mirum Pharmaceuticals, H-UM consults for Metabogen, CW consults for GlaxoSmithKlein.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"51"}}